Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-04-24

Eton Pharmaceuticals (ETON)

CEO Sean Brynjelsen was paid $2,914,489 in fiscal year 2025, ↑ up 20.8% from fiscal year 2024 (SEC filing 0001437749-26-013313 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,914,489 ↑
Sean Brynjelsen total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
93.7%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Sean Brynjelsen (President and Chief Executive Officer), FY2025 total compensation $2,914,489 (base salary $712,433) [exec_comp, SEC accession 0001437749-26-013313, filed 2026-04-24]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

ETON's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Sean Brynjelsen$712,433$0$936,052$893,712$354,792$0$17,500$2,914,489
President and Chief Executive Officer
James Gruber460,4600336,388321,172171,9820108,0661,398,068
Chief Financial Officer
David Krempa460,4600336,388321,172171,9820104,7431,394,745
Chief Business Officer
Ipek Erdogan-Trinkaus402,722000150,417022,153575,292
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Sean Brynjelsen$2,914,489$2,411,923$1,747,045↑ +502,566
James Gruber1,398,0681,075,080785,140↑ +322,988
David Krempa1,394,7451,325,083719,080↑ +69,662
Ipek Erdogan-Trinkaus575,292775,488—↓ −200,196

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Eton Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper ETON reports.

We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against ETON
1 company names ETON as a compensation peer

Each company listed discloses ETON in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ETON in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
David KrempaChief Business Officer$1,394,745
James GruberCFO$1,398,068
Sean BrynjelsenCEO$2,914,489
Ipek Erdogan-TrinkausCCO$575,292
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Charles J. CasamentoIndependent Director$275,139
Jenn AdamsIndependent Director$267,027
Norbert G. Riedel, Ph.DChair of the Board$318,047
Paul V. MaierIndependent Director$277,843
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Sean BrynjelsenRSA———1,000,000——
03b

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
James GruberOption25,0003.81—
David KrempaOption6,5953.78—
Sean BrynjelsenRSU72,004—1,217,588
David KrempaOption29,77113—
Sean BrynjelsenOption237,5934.42—
Sean BrynjelsenOption82,84113—
Ipek Erdogan-TrinkausOption56,25012.46—
David KrempaRSU31,566—533,781
Sean BrynjelsenRSU27,500—465,025
Sean BrynjelsenOption102,1953.47—
James GruberRSU25,876—438,563
David KrempaRSU25,876—438,563
James GruberRSU10,000—169,100
David KrempaRSU10,000—169,100
Ipek Erdogan-TrinkausRSU6,020—101,798
James GruberOption29,77113—
James GruberOption78,3674.42—
James GruberOption29,1923.47—
David KrempaOption78,3674.42—
David KrempaOption21,6663.47—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company considers compensation for comparable positions in the market, historical compensation levels, individual performance, and the desire to motivate employees to achieve short- and long-term results in the best interests of stockholders.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantRadford, an Aon company
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-119,170,839553,04363,36493.7%Passed
20232023-06-13—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20242024-06-1193.7%a
20232023-06-13—b

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have the effect of a vote "against" (i) the advisory vote on executive compensation (ii) the appointment of KMJ Corbin & Company LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.”.

b. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Norbert G. Riedel, Ph.DIndependent · Board Chair · Audit · Compensation · Nominating and Corporate Governance (Chair)$123,672—$194,375——$318,047
Paul V. MaierIndependent · Audit (Chair) · Nominating and Corporate Governance · Compensation83,468—194,375——277,843
Charles J. CasamentoIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance80,764—194,375——275,139
Jenn AdamsIndependent · Audit · Compensation · Nominating and Corporate Governance72,652—194,375——267,027
Sean E. BrynjelsenEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer—
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$360,556
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$360,556

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eton Pharmaceuticals2025Sean Brynjelsen$712,433$936,052$893,712$354,792$2,914,489

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Eton Pharmaceuticals in fiscal 2025?
As disclosed, Sean Brynjelsen (President and Chief Executive Officer) was the highest-paid executive at Eton Pharmaceuticals in fiscal 2025, with total compensation of $2,914,489.
How did shareholders vote on Eton Pharmaceuticals's executive compensation?
As disclosed, 93.7% of shareholders supported Eton Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Eton Pharmaceuticals spend in total on board compensation for fiscal 2025?
As disclosed, Eton Pharmaceuticals reported total board compensation of $360,556 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Sean BrynjelsenDEF 14A2026-04-240001437749-26-013313Section “Executive Compensation”. As printed: 2,914,489. View filing ↗
2Section 01, James GruberDEF 14A2026-04-240001437749-26-013313Section “Executive Compensation”. As printed: 1,398,068. View filing ↗
3Section 01, David KrempaDEF 14A2026-04-240001437749-26-013313Section “Executive Compensation”. As printed: 1,394,745. View filing ↗
4Section 01, Ipek Erdogan-TrinkausDEF 14A2026-04-240001437749-26-013313Section “Executive Compensation”. As printed: 575,292. View filing ↗
5Section 03, Sean Brynjelsen RSADEF 14A2026-04-240001437749-26-013313Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
6Section 08, Norbert G. Riedel, Ph.DDEF 14A2026-04-240001437749-26-013313Section “Director Compensation”. As printed: 318,047. View filing ↗
7Section 08, Paul V. MaierDEF 14A2026-04-240001437749-26-013313Section “Director Compensation”. As printed: 277,843. View filing ↗
8Section 08, Charles J. CasamentoDEF 14A2026-04-240001437749-26-013313Section “Director Compensation”. As printed: 275,139. View filing ↗
9Section 08, Jenn AdamsDEF 14A2026-04-240001437749-26-013313Section “Director Compensation”. As printed: 267,027. View filing ↗
10Section 08, Sean E. BrynjelsenDEF 14A2026-04-240001437749-26-013313Section “Director Compensation”. As printed: 0. View filing ↗
11Section 06, 2024 voteForm 8-K2024-06-110001437749-24-019953Item 5.07 · say-on-pay result. As reported: 93.7% (votes for as printed: 9,170,839). View filing ↗
12Section 06, 2023 voteForm 8-K2023-06-130001493152-23-021064Item 5.07 · say-on-pay result. As reported: —. View filing ↗
13Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.
14Section 09b board cost (computed)Computed——Cash 360,556 + equity 0 + all other 0 = 360,556, summed across the director compensation table rows.
15Eton Pharmaceuticals (subject), Section 10b CEO totalDEF 14A2026-04-240001437749-26-013313CEO total compensation as printed in Eton Pharmaceuticals's own proxy. As printed: 2,914,489. View filing ↗